SM
TCRT icon

Sabby Management’s Alaunos Therapeutics TCRT Stock Holding History

Sabby Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10
Closed -$667K – 287
2014
Q1 		$667K Sell
10
-7
-41% -$4.69K 0.04% 160
2013
Q4 		$1.11M Buy
17
+5
+42% +$2.98K 0.07% 110
2013
Q3 		$712K Buy
+12
New +$5.41K 0.05% 141

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's TCRT Position: Q2 2014 in Review

Sabby Management sold out of Alaunos Therapeutics (TCRT) in Q2 2014, closing a stake of 737 shares — an estimated $410K sold.

Sabby Management first reported a position in TCRT in Q1 2014 and held it in 1 quarter. The position peaked at $506K in Q1 2014. 92 funds tracked by Wall St. Rank hold TCRT as of Q2 2014.

  • Sabby Management reported no remaining Alaunos Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Sabby Management sold 737 Alaunos Therapeutics shares in Q2 2014, an estimated $410K.
  • Sabby Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 1 quarter.
  • Sabby Management's Alaunos Therapeutics position peaked at $506K in Q1 2014.
  • 92 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2014.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.